NICE no for Pierre Fabre’s Braftovi
Preliminary guidelines reject NHS funding for the drug for BRAF V600E mutation-positive metastatic colorectal cancer
Read More
Tag: cetuximab
EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
Merck’s Erbitux backed by NICE for head and neck cancer
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
Read More
NICE expands reach of Erbitux in colorectal cancer
Cost regulators for the NHS treatments in England and Wales are expanding the scope of Merck’s Erbitux so that the therapy will be routinely available to treat a wider range of patients with metastatic colorectal cancer (mCRC).
Read More
Researchers uncover cetuximab resistance pathway in bowel cancer
Researchers from Queen’s University, Belfast, have discovered that blocking a certain molecule could help side-step resistance to cetuximab in bowel cancer patients.
Read More
NICE rejects Merck’s Erbitux
The National Institute for Health and Care Excellence has decided that use of Merck’s head and neck cancer drug Erbitux is not cost-effective for the NHS in England and Wales.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
